Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Anna L. Reid"'
Autor:
Leslie Calapre, Tindaro Giardina, Aaron B. Beasley, Anna L. Reid, Colin Stewart, Benhur Amanuel, Tarek M. Meniawy, Elin S. Gray
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-7 (2023)
Abstract Plasma circulating tumour DNA (ctDNA) has been suggested to be a viable biomarker of response to treatment in patients with high grade serous ovarian carcinoma (HGSOC). TP53 mutations are present in more than 90% of HGSOCs but somatic varian
Externí odkaz:
https://doaj.org/article/4563136ea8714a7294842de73f101b88
Autor:
Leslie Calapre, Tindaro Giardina, Cleo Robinson, Anna L. Reid, Zeyad Al‐Ogaili, Michelle R. Pereira, Ashleigh C. McEvoy, Lydia Warburton, Nicholas K. Hayward, Muhammad A. Khattak, Tarek M. Meniawy, Michael Millward, Benhur Amanuel, Melanie Ziman, Elin S. Gray
Publikováno v:
Molecular Oncology, Vol 13, Iss 2, Pp 171-184 (2019)
Circulating tumor DNA (ctDNA) may serve as a surrogate to tissue biopsy for noninvasive identification of mutations across multiple genetic loci and for disease monitoring in melanoma. In this study, we compared the mutation profiles of tumor biopsie
Externí odkaz:
https://doaj.org/article/98c3acf65a924037b07e2a94d106762e
Autor:
Muhammad A. Khattak, Afaf Abed, Anna L. Reid, Ashleigh C. McEvoy, Michael Millward, Melanie Ziman, Elin S. Gray
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: The development of biomarkers predictive of response to immune checkpoint inhibitor (ICI) therapies in advanced melanoma is an area of great interest in oncology. Our study evaluated the potential role of serum vascular endothelial growth
Externí odkaz:
https://doaj.org/article/9cad988efa804ec5a21b3a6fd9067c56
Autor:
Michael Millward, Michelle R. Pereira, Leslie Calapre, Afaf Abed, Tarek Meniawy, Gabriela Marsavela, Zeyad Al-Ogaili, Elin S. Gray, Lydia Warburton, Melanie Ziman, Ashleigh C. McEvoy, Anna L. Reid, Muhammad A. Khattak
Publikováno v:
British Journal of Cancer. 126:401-408
Background The validity of circulating tumour DNA (ctDNA) as an indicator of disease progression compared to medical imaging in patients with metastatic melanoma requires detailed evaluation. Methods Here, we carried out a retrospective ctDNA analysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74fdbe9d12da99293d0848811f77cd02
https://doi.org/10.1038/s41416-021-01507-6
https://doi.org/10.1038/s41416-021-01507-6
Autor:
Afaf Abed, Leslie Calapre, Jenny H. Lee, Gabriela Marsavela, Michael Millward, Matteo S. Carlino, Sarah-Jane Dawson, Benhur Amanuel, Elin S. Gray, Michelle R. Pereira, Tarek Meniawy, Richard A. Scolyer, Anna L. Reid, Muhammad A. Khattak, Stephen Q. Wong, Alexander M. Menzies, Cleo Robinson, Lydia Warburton, Ashleigh C. McEvoy, Shahneen Sandhu, Georgina V. Long, Melanie Ziman, Helen Rizos
Publikováno v:
Clinical Cancer Research. 26:5926-5933
Purpose: We evaluated the predictive value of pretreatment ctDNA to inform therapeutic outcomes in patients with metastatic melanoma relative to type and line of treatment. Experimental Design: Plasma circulating tumor DNA (ctDNA) was quantified in 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12eaf6103145b2ba447717a902a90381
https://doi.org/10.1158/1078-0432.ccr-20-2251
https://doi.org/10.1158/1078-0432.ccr-20-2251
Autor:
Muhammad A Khattak, Oliver Oey, Aesha Gandhi, Anna L Reid, Afaf Abed, Leslie Calapre, Michael Morici, Abha Chopra, Tarek Meniawy, Michael Millward, Melanie Ziman, Elin S Gray
Background:Predictive biomarkers of response to immune checkpoint inhibitors (ICI) are currently being evaluated in many studies. We evaluated whether germline Human Leukocyte Antigen (HLA) status can influence the response to immunotherapy.Materials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b70f22993107fe47eff1d37e4e48aa60
https://doi.org/10.21203/rs.3.rs-1360151/v1
https://doi.org/10.21203/rs.3.rs-1360151/v1
Autor:
Leslie, Calapre, Tindaro, Giardina, Aaron B, Beasley, Anna L, Reid, Colin, Stewart, Benhur, Amanuel, Tarek M, Meniawy, Elin S, Gray
Publikováno v:
Scientific reports. 13(1)
Plasma circulating tumour DNA (ctDNA) has been suggested to be a viable biomarker of response to treatment in patients with high grade serous ovarian carcinoma (HGSOC). TP53 mutations are present in more than 90% of HGSOCs but somatic variants are di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0d1adc7cf1a4b1e33fe18174a6874357
https://pubmed.ncbi.nlm.nih.gov/36609632
https://pubmed.ncbi.nlm.nih.gov/36609632
Autor:
Tersia Vermeulen, Riyaz Bhikoo, Doireann Hennessy, Michelle R. Pereira, Leslie Calapre, Jacqueline M. Bentel, R. Max Conway, Bob Mirzai, Melanie Ziman, Elin S. Gray, Aaron B. Beasley, Timothy Isaacs, Wendy N. Erber, James Freeman, Fred K. Chen, Jean-Louis DeSousa, Daniel McKay, Anna L. Reid
Publikováno v:
Cancers
Cancers; Volume 13; Issue 23; Pages: 5990
Cancers, Vol 13, Iss 5990, p 5990 (2021)
Cancers; Volume 13; Issue 23; Pages: 5990
Cancers, Vol 13, Iss 5990, p 5990 (2021)
Simple Summary Approximately 50% of patients with uveal melanoma will develop incurable metastatic disease. This can be predicted, but requires a biopsy of the eye, which outside of centres of excellence, are not routinely performed. Given that uveal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6295aaf4f2837488460e7747e9491a4d
http://europepmc.org/articles/PMC8657240
http://europepmc.org/articles/PMC8657240
Autor:
Yuchun Luo, Zili Zhai, Dexiang Gao, Anna L. Reid, Mayumi Fujita, Carol M. Amato, Charles A. Dinarello, Douglas G. Osborne, Melanie Ziman, William A. Robinson, Joanne Domenico
Publikováno v:
Mol Carcinog
Immune suppression is one of the 10 hallmarks of cancer. Interleukin-37 (IL-37), a member of the IL-1 family, inhibits both innate and adaptive immunity, and has been shown to modulate immune responses in various disease conditions. Yet, IL-37 has ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a391f1d4b376aecc6475a75ae1eb792
https://doi.org/10.1002/mc.23044
https://doi.org/10.1002/mc.23044
Autor:
Nicholas K. Hayward, Leslie Calapre, Michael Millward, Michelle R. Pereira, Elin S. Gray, Cleo Robinson, Tarek Meniawy, Benhur Amanuel, Zeyad Al-Ogaili, Tindaro Giardina, Ashleigh C. McEvoy, Muhammad A. Khattak, Anna L. Reid, Lydia Warburton, Melanie Ziman
Publikováno v:
Molecular Oncology
Molecular Oncology, Vol 13, Iss 2, Pp 171-184 (2019)
Molecular Oncology, Vol 13, Iss 2, Pp 171-184 (2019)
Circulating tumor DNA (ctDNA) may serve as a surrogate to tissue biopsy for noninvasive identification of mutations across multiple genetic loci and for disease monitoring in melanoma. In this study, we compared the mutation profiles of tumor biopsie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::742898ec889f54834481890c8d9c56f4
http://europepmc.org/articles/PMC6360370
http://europepmc.org/articles/PMC6360370